mAbxience and Sandoz have entered a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar candidate referencing Hemlibra. mAbxience will develop and manufacture the medicine at GMP-approved facilities in Spain and Argentina, while Sandoz will hold exclusive commercialization rights worldwide except in Argentina, Uruguay and Paraguay. The financial terms are confidential. The candidate would expand mAbxience's pipeline into haemophilia A and rare diseases, while addressing a reference market estimated at approximately $5.7 billion. Hemophilia A, caused by insufficient or defective factor VIII, accounts for around 80% of hemophilia cases worldwide. The companies said the deal combines mAbxience's development and manufacturing platform with Sandoz's global commercial reach as biologic medicines approach loss of exclusivity.